Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1222 • ACR Convergence 2020
Iron Management in Patients with Rheumatoid Arthritis
Wojciech Tański¹, Mariusz Chabowski² and Ewa Jankowska³, ¹4th Military Teaching Hospital, Wrocław, Poland, ²4th Military Teaching Hospital, Wroclaw Medical University, Wrocław, Poland, ³Wroclaw Medical University, Wrocław, Poland
Background/Purpose: Rheumatoid arthritis (RA) is a chronic connective tissue disease with immune background, which affects approximately 0.3-2% of the population. Anaemia is the most common…
Abstract Number: 1240 • ACR Convergence 2020
An Increase in Red Cell Mean Corpuscular Volume by Methotrexate Is Potentiated by Hydroxychloroquine and Predicts Clinical Response in Rheumatoid Arthritis
Muhammad Shipa¹, Su-Ann Yeoh¹, Dev Mukerjee² and Michael Ehrenstein¹, ¹University College London, LONDON, United Kingdom, ²North Middlesex University hospital NHS Trust, London, United Kingdom
Background/Purpose: Methotrexate (MTX) can result in an increase in mean corpuscular volume (MCV) of red blood cells. The range of MCV change varies between patients…
Abstract Number: 1464 • ACR Convergence 2020
Multi-Variate Approach Including Serology and Genetics for an Improved Identification of Patients at Risk of Developing Rheumatoid Arthritis
Céline Lamacchia¹, Maresa Grundhuber², Isabel Gehring², Pascale Roux Lombard³, Michael John Nissen¹, Andrea Rubbert Roth⁴, Ruediger Mueller⁵, Ulrich Walker⁶, Burkhard Moeller⁷, Diego Kyburz⁸, Adrian Ciurea⁹, Sascha Swiniarski¹⁰ and Axel Finckh¹¹, ¹Geneva University Hospital, Geneva - 14, Switzerland, ²Thermo Fisher Scientific Phadia GmbH, Freiburg, Germany, ³Geneva University Hospital, Geneva, Switzerland, ⁴Klinik für Rheumatologie, Kantonsspital St Gallen, St Gallen, Sankt Gallen, Switzerland, ⁵KSA: Aarau Hospital, Aarau, Switzerland, ⁶Basel University Hospital, Basel, Switzerland, ⁷Inselspital - University Hospital Bern, Bern, Switzerland, ⁸University Hospital Basel, Basel, Switzerland, ⁹University Hospital Zurich, Zurich, Switzerland, ¹⁰Phadia GmbH / Thermo Fisher Scientific, Freiburg, Germany, ¹¹Division of Rheumatology, University Hospitals of Geneva, Geneva, Switzerland
Background/Purpose: First-degree relatives of RA patients (FDR-RA) have an increased prevalence for rheumatoid arthritis (RA) [1] and joint symptoms [2]. Identification of individuals with imminent RA…
Abstract Number: 1540 • ACR Convergence 2020
Association Between Disease Activity and Left Ventricular Systolic Function in Patients with Rheumatoid Arthritis: A Case-Control Study
Elías Abraham Rodríguez¹, Dionicio Ángel Galarza-Delgado², José Ramón Azpiri López³, Iris Jazmín Colunga Pedraza⁴, Salvador Lugo Pérez³, Itzel Corina Zárate Salinas³, Paola Fernanda Frausto Lerma⁴, Alejandra Pérez Villar⁴, Mayra Alejandra Reyes Soto⁴ and Raymundo Vera⁵, ¹Hospital Universitario "José Eleuterio González", Monterrey, Mexico, ²Rheumatology Service, Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma Nuevo León, Monterrey, Nuevo Leon, Mexico, ³Cardiology Service, Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma Nuevo León, Monterrey, Mexico, ⁴Rheumatology service, Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma Nuevo León, Monterrey, Mexico, ⁵Cardiology Service Hospital Universitario "José Eleuterio González", Monterrey, Mexico
Background/Purpose: Patients with Rheumatoid Arthritis(RA) have a higher prevalence of Cardiovascular Disease (CVD), which is the most common cause of death in this group. Disease…
Abstract Number: 1603 • ACR Convergence 2020
P4 Index Correlates with RAPID3 and Disease-Specific Indices in Rheumatoid Arthritis (RA) and Axial Spondyloarthritis (axSpA)
Abhijeet Danve¹, Betty Hsiao² and Phillip Zhang³, ¹Yale University, Rocky Hill, CT, ²Yale Rheumatology, New Haven, ³Yale University, New Haven, CT
Background/Purpose: RAPID3 scores correlate well with disease-specific indices, including the Clinical Disease Activity Index (CDAI) in RA and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)…
Abstract Number: 1724 • ACR Convergence 2020
A Feasible and Efficient Approach to Implementing Rheumatoid Arthritis Disease Activity Measure in a Busy Rheumatology Clinic: A Quality Improvement Project
Ali H.Ali¹, Amani Elghafri², Mosaab Mohameden³, Mandeep Sidhu² and Candice Reyes Yuvienco⁴, ¹University of California San Francisco Fresno, Fresno, CA, ²University of California San Francisco Fresno, Fresno, ³University of Cincinnati, Cincinnati, OH, ⁴University of California San Francisco Fresno, Clovis, CA
Background/Purpose: The treatment of Rheumatoid Arthritis (RA) has witnessed a substantial change over last the 20 years, with disease remission becoming an achievable goal. Treat-to-target…
Abstract Number: 1741 • ACR Convergence 2020
Does Preventive Care Matter? (in RA)
Morgan Greenwald¹, JoAnn Ball¹, Shannon Lopez¹, Monica Berg¹ and Maria Greenwald¹, ¹Desert Medical Advances, Palm Desert, CA
Background/Purpose: Preventive medical care improves morbidity and mortality. The assessment included 28,105 RA patients from prospective randomized trials.Methods: Nested data from a single site was…
Abstract Number: 1758 • ACR Convergence 2020
Prevalence and Incidence of Infection and Venous Thromboembolism in Rheumatoid Arthritis Patients Newly Initiating Various DMARD Classes: Real-World Analysis of 2012–2016 US Medicare Data
Robin Dore¹, Jenya Antonova², Lawrence Chang², Suying Li³, Haifeng Guo³, Yuanyuan Ji³ and Mark Genovese⁴, ¹Private practice, Tustin, CA, ²Gilead Sciences, Foster City, CA, ³Chronic Disease Research Group, Minneapolis, MN, ⁴Stanford University Medical Center, Palo Alto, CA
Background/Purpose: RA patients have an increased risk of infection1 and venous thromboembolism (VTE)2. Although rates of serious infection and VTE have been reported for Medicare…
Abstract Number: 1958 • ACR Convergence 2020
Patterns and Impact of Long-term Glucocorticoid Use on RA Patients at Risk for Major Adverse Cardiac Events
Beth Wallace¹, Yuqing Gao², Punyasha Roul³, Bryant England³, Ted Mikuls³, Shirley Cohen-Mekelburg⁴, Daniel Clauw⁵, Rodney Hayward¹ and Akbar Waljee¹, ¹Michigan Medicine, VA Ann Arbor Healthcare System Center for Clinical Management Research, Ann Arbor, MI, ²VA Ann Arbor Healthcare System, Center for Clinical Management Research, Ann Arbor, MI, ³University of Nebraska Medical Center, Omaha, NE, ⁴Michigan Medicine/VA Ann Arbor Healthcare System Center for Clinical Management Research, Ann Arbor, MI, ⁵Michigan Medicine, Ann Arbor, MI
Background/Purpose: One-quarter to one-third of RA patients use long-term glucocorticoids (GCs) despite their known, dose-dependent association with increased risk of major adverse cardiovascular (CV) events…
Abstract Number: 2000 • ACR Convergence 2020
Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients Treated with Methotrexate versus Hydroxychloroquine
Mengdong He¹, Ajinkya Pawar¹, Rishi Desai¹, Robert Glynn¹, Hemin Lee¹, Michael Weinblatt¹, Daniel H Solomon¹ and Seoyoung Kim¹, ¹Brigham and Women's Hospital, Boston, MA
Background/Purpose: Prior studies suggest an increased risk of venous thromboembolism (VTE) among patients with rheumatoid arthritis (RA). However, little is known about the comparative risk…
Abstract Number: 2047 • ACR Convergence 2020
Synovial CD8 T Cells in Rheumatoid Arthritis Exhibit High Antigen-independent Cytokine Production and Low Cytotoxic Potential
Anna Helena Jonsson¹, Fan Zhang², Emma Gomez-Rivas³, Karishma Rupani⁴, Gerald Watts⁵, Kevin Wei¹, Runci Wang⁴, Deepak Rao⁴, Accelerating Medicines Partnership (AMP) - RA/SLE⁶, Soumya Raychaudhuri² and Michael Brenner¹, ¹Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ³Division of Rheumatology, Brigham and Women's Hospital, Boston, MA, ⁴Brigham and Women's Hospital, Boston, MA, ⁵Brigam and Women's Hospital, Boston, ⁶., Boston
Background/Purpose: T cell-derived pro-inflammatory cytokines are major drivers of RA pathogenesis, and these cytokines have traditionally been attributed to CD4 T cells. However, single-cell RNA-sequencing…
Abstract Number: 0016 • ACR Convergence 2020
Differential Characteristics in Inflammatory Rheumatologic Patients with Severe and Mild COVID-19 Infection
Paula García Escudero¹, Claudia Stoye², Orlando Pompei fernández², Marta González Fernández¹, Joaquín María Belzunegui Otano³, Juan Ramón De Dios², Belén Álvarez Rodríguez², Elena Garmendia Sánchez¹, Susana Gil², Ana Ruibal-Escribano⁴, Margarida Vasques Rocha², Francisco García Llorente⁵, César Antonio Egües⁶, Edurne Guerrero⁷ and Jaime Calvo-Alén², ¹Hospital Universitario Cruces, Barakaldo, Spain, ²Hospital Universitario Araba, Vitoria-Gasteiz, Pais Vasco, Spain, ³Rheumatology Service, Hospital Universitario Donostia. San Sebastián, Spain, San Sebastian, Spain, ⁴Hospital Alfredo Espinosa, Urduliz, Pais Vasco, Spain, ⁵Hospital Universitario de Galdakao, Galdakao, Pais Vasco, Spain, ⁶Hospital Universitario Donostia, Donostia-San Sebastián, Pais Vasco, Spain, ⁷Hospital Alto Deba, Arrasate, Pais Vasco, Spain
Background/Purpose: SARS COV 2 pandemic has been an issue which has challenged the health care systems around the world. Rheumatology has been involved in two…
Abstract Number: 0071 • ACR Convergence 2020
Significant Enrichment of Transcriptionally Distinct CD206+CD163+ Macrophage Population in Rheumatoid Arthritis Synovial Tissue
Megan Hanlon¹, Mary Canavan², Qingxuan Song³, Candice Low⁴, Phil Gallagher⁵, Ronan Mullan⁶, Conor Hurson⁷, Sunil Nagpal⁸, Douglas Veale⁹ and Ursula Fearon², ¹Molecular Rheumatology, Trinity College Dublin, Dublin 2, Dublin, Ireland, ²Molecular Rheumatology, Trinity College Dublin, Dublin, Dublin, Ireland, ³Janssen Research & Development, LLC, Spring House, PA, USA, Spring House, PA, ⁴EULAR Centre for Arthritis and Rheumatic diseases, St Vincents University Hospital, UCD, Dublin, Ireland, ⁵St Vincents University Hospital, UCD, Dublin, Ireland, ⁶Adelaide and Meath Hospital, Dublin, Dublin, Ireland, ⁷St Vincents University Hospital, UCD, Dublin, Dublin, Ireland, ⁸Janssen Research & Development, Collegeville, PA, ⁹EULAR Centre for Arthritis and Rheumatic Diseases, St Vincents University Hospital, UCD, Dublin, Dublin, Ireland
Background/Purpose: Synovial tissue macrophages are an exquisitely plastic pool of innate cells that play a key role in RA disease progression. However, the precise nature,…
Abstract Number: 0141 • ACR Convergence 2020
Filgotinib Improved Work Productivity and Activity Impairment in Patients with Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results from FINCH-1 Study
Zobair Younossi¹, Maria Stepanova², Lynn Gerber¹, Susan Lee³, Hao Hu³, Thijs Hendrikx⁴, Annelies Boonen⁵, David Walker⁶, Rieke Alten⁷ and Bernard Combe⁸, ¹Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, VA, ²Center for Outcomes Research in Liver Disease, Washington, DC, ³Gilead Sciences, Inc., Foster City, CA, ⁴Galapagos BV, Leiden, Netherlands, ⁵Maastricht University Medical Center, Maastricht, Netherlands, ⁶Northumbria Healthcare Trust, North Shields, United Kingdom, ⁷Schlosspark-Klinik, Universitätsmedizin, Berlin, Germany, ⁸University of Montpellier, Montpellier, France
Background/Purpose: Filgotinib (FIL) is a potent oral selective janus kinase 1 inhibitor which is currently being investigated as an agent to treat rheumatoid arthritis (RA).…
Abstract Number: 0179 • ACR Convergence 2020
Identification of Multimorbidity Patterns in Rheumatoid Arthritis Through Machine Learning
Bryant England¹, Yangyuna Yang¹, Punyasha Roul¹, Christian Haas², Lotfollah Najjar², Harlan Sayles¹, Fang Yu¹, Brian Sauer³, Joshua Baker⁴, Kaleb Michaud¹, Fenglong Xie⁵, Jeffrey R Curtis⁶ and Ted Mikuls¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Nebraska Omaha, Omaha, NE, ³University of Utah, Omaha, NE, ⁴University of Pennsylvania, Philadelphia, PA, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Chronic conditions often complicate the disease course of rheumatoid arthritis (RA) and predispose to poor long-term outcomes. The interrelationship of individual chronic conditions and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.